Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction

Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction

US Patent 11771671 · Granted Oct 3, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods of treating developmental disorders with gaboxadol2025
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and 2025
Methods and compositions for treatment of epileptic disorders2024
Methods and compositions for treatment of epileptic disorders2024
Methods of treating seizure disorders and Prader-Willi syndrome2024
Methods and compositions for treatment of epileptic disorders2024
Methods and compositions for treatment of epileptic disorders2024
Methods and compositions for treatment of epileptic disorders2023
Use of MIR101 or MIR128 in the treatment of seizure disorders2023
Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder2023
Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and 2023
Methods and compositions for treatment of epileptic disorders2022